Plain-English translation of NCT06829563 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called to see if it is safe and how the body processes it. The study will enroll healthy volunteers and people with type 2 diabetes to understand whether this treatment works well and causes any side effects.
Researchers are developing this medication as a potential new option for treating type 2 diabetes. This early-stage trial is designed to understand if the treatment is safe and how it behaves in the human body before testing it more widely.
You likely qualify if…
You likely don't qualify if…
Participants will be assigned to different study groups. Some will receive the new medication as a single dose or multiple doses, while others receive a placebo (inactive pill) for comparison. You'll check into a research clinic for observation, have blood drawn to monitor safety and how your body processes the medication, and may be asked to take doses with food or without food to see how that affects the treatment. The study has three parts and involves visits over several weeks.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Australia
Phase
Safety & dosing
Sponsor
Rezubio Pharmaceuticals Co., Ltd.
Enrollment target
~134 participants
Started
January 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dr. Tang
Rezubio Pharmaceuticals Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.